Joao M. Silva-Oliveira

Alfenas, MG, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Non-clonal interphase markers of chromosomal instability in malignancy acquisition and cancer progression.

Non-clonal interphase markers of chromosomal instability in malignancy acquisition and cancer progression.

Journal: Mutation research

Published: March 21, 2026

Quantitative and qualitative methods for measuring chromosomal instability in tumor cells.

Quantitative and qualitative methods for measuring chromosomal instability in tumor cells.

Journal: Cancer genetics

Published: September 22, 2025

Hydroethanolic Soy Extract Rich in Isoflavones Protects Dystrophic Mutant Mice From Oxidative Stress and Inflammation via the ROS/NF-κB Feedback Pathway.

Hydroethanolic Soy Extract Rich in Isoflavones Protects Dystrophic Mutant Mice From Oxidative Stress and Inflammation via the ROS/NF-κB Feedback Pathway.

Journal: BioFactors (Oxford, England)

Published: April 23, 2025

HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells.

HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells.

Journal: Investigational new drugs

Published: November 04, 2024

WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.

WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.

Journal: Cancer chemotherapy and pharmacology

Published: September 01, 2024

HDAC6: Tumor Progression and Beyond.

HDAC6: Tumor Progression and Beyond.

Journal: Current cancer drug targets

Published: July 24, 2024

HDAC6: Tumor Progression and Beyond.

HDAC6: Tumor Progression and Beyond.

Journal: Current cancer drug targets

Published: July 24, 2024

Treatment With Full-Spectrum Cannabidiol Oil Improved the Pathological Findings of Dystrophic Mutant Mice.

Treatment With Full-Spectrum Cannabidiol Oil Improved the Pathological Findings of Dystrophic Mutant Mice.

Journal: Muscle & nerve

Published: May 01, 2024

Showing 1-8 of 8

Last Updated: 09/26/2026